BIOFRONTERA INC. WARRANTS
NASDAQ: BFRIW (Biofrontera Inc. Warrants)
Last update: 2 days ago, 11:36PM0.040
0.01 (22.70%)
Previous Close | 0.033 |
Open | 0.040 |
Volume | 3,006 |
52 Weeks Range |
Profit Margin | -47.58% |
Operating Margin (TTM) | -13.63% |
Diluted EPS (TTM) | -1.30 |
Quarterly Revenue Growth (YOY) | 18.50% |
Total Debt/Equity (MRQ) | 111.03% |
Current Ratio (MRQ) | 1.72 |
Operating Cash Flow (TTM) | -10.27 M |
Levered Free Cash Flow (TTM) | -5.12 M |
Return on Assets (TTM) | -43.00% |
Return on Equity (TTM) | -384.98% |
Market Trend
Short Term | Medium Term | ||
Industry | Drug Manufacturers - Specialty & Generic (US) | Bearish | Mixed |
Drug Manufacturers - Specialty & Generic (Global) | Bearish | Mixed | |
Stock | Biofrontera Inc. Warrants | - | - |
AIStockmoo Score
Analyst Consensus | -2.0 |
Insider Activity | NA |
Price Volatility | NA |
Technical Moving Averages | 0.0 |
Technical Oscillators | 0.0 |
Average | -0.67 |
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, a prescription drug for use in combination with the BF-RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts. |
|
Sector | Healthcare |
Industry | Drug Manufacturers - Specialty & Generic |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2025 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |